GI CANCERS

Rachna Shroff, MD, details key data from the phase III GASTFOX study comparing FOLFOX to docetaxel (TFOX) in the first line treatment of advanced gastric cancer.

Expert medical oncologists review data from the CABINET trial evaluating cabozantinib compared with placebo in two cohorts of previously treated patients with neuroendocrine tumors.

Rachna Shroff, MD, chief of the Division of Hematology and Oncology in the Department of Medicine at the University of Arizona College of Medicine, highlights key data from the Codebreak300 study evaluating if the combination of sotorasib and panitumumab is superior to standard-of-care trifluridine/tipiracil or regorafenib in the setting of chemorefractory metastatic colorectal cancer.

Pembrolizumab and fluoropyrimidine- and platinum-containing chemotherapy are now FDA-approved for the treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

This companion diagnostic tool, which is already approved for use in 5 other cancer types, identifies patients who may be suited for treatment with pembrolizumab.

In an interview for World Neuroendocrine Cancer Awareness Day, Casey J. Allen, MD, discussed the advances in treatment for these patients with gastrointestinal neuroendocrine tumors.

TX-030, a potential first-in-class, anti-CD39 antibody, is being evaluated in a phase 2 trial in metastatic pancreatic ductal adenocarcinoma.

The phase 3 EMERALD-1 trial has met its primary end point and continues to assess durvalumab combined with transarterial chemoembolization and bevacizumab for the secondary end point of overall survival in patients with hepatocellular carcinoma.

The updated indication limits the use of pembrolizumab and chemotherapy to tumors expressing PD-L1 as determined by an FDA-approved test.

Fruquintinib is a new, well-tolerated option for the treatment of patients with refractory metastatic colorectal cancer.

Combining sotorasib and panitumumab improved progression-free survival for patients with KRAS G12C mutation in metastatic colorectal cancer, based on the phase 3 CodeBreaK 300 trial.

CMG901 was active and had a manageable safety profile in a heavily pretreated population of patients with CLDN18.2-positive gastric/gastroesophageal junction cancer.

Irrespective of PD-L1 expression, patients treated with domvanalimab, zimberelimab, and chemotherapy in arm A1 of the phase 2 EDGE-Gastric study demonstrated promising overall response rate and 6-month progression-free survival results.

Encouraging progression-free survival and ctDNA molecular response rates were seen with SD-101 delivered via pressure-enabled drug delivery plus intravenous checkpoint inhibitors in patients with metastatic uveal melanoma with liver metastases.

The approval of pembrolizumab with gemcitabine and cisplatin offers a new immunotherapy regimen for patients with locally advanced unresectable or metastatic biliary tract cancer.

Tracy Proverbs-Singh, MD, and Steven Lee-Kong, MD, reflect on how to incorporate sequencing and personalized treatments effectively in oncology practice.

Key opinion leaders explore the evolving landscape of precision medicine in gastrointestinal cancers and how molecular profiling is transforming treatment decisions for patients.

TAC01-HER2, an autologous TAC-T cell lead asset made to target HER2 in relapsed or refractory gastric and gastroesophageal junction tumors, is being further evaluated in phase 2 of the TACTIC-2 study.

Shared insight into the latest developments in immunotherapy and novel treatment options for colorectal cancer, including ongoing trials and the pursuit of new targets to enhance the immune response against cancer.

Tracy Proverbs-Singh, MD, and Steven Lee-Kong, MD, explore the forefront of colorectal cancer treatment, featuring targeted therapies, immunotherapy options, and the power of multidisciplinary teamwork.

The safety run-in of the LEAP-014 trial showed acceptable toxicity and antitumor responses in patients with metastatic esophageal cancer receiving pembrolizumab, lenvatinib, and chemotherapy consisting of cisplatin plus either paclitaxel or 5-fluororacil.

The addition of pembrolizumab to trastuzumab plus chemotherapy improved progression-free survival in the first-line for patients with metastatic HER2-positive gastric or gastroesophageal junction cancer.

The addition of durvalumab to standard-of-care chemotherapy shows potential to improve downstaging in patients with resectable gastroesophageal junction and gastric cancer, according to findings from the phase 3 MATTERHORN study.

New data from the phase 3 RATIONALE 305 trial of tislelizumab with chemotherapy show potential of the combination for patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma.

Expert perspectives on comprehensive treatment strategies for metastatic colorectal cancer, including systemic therapies, precision medicine, and the potential for cure.